Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;8(10):2047-2066.
doi: 10.1038/s41562-024-01924-6. Epub 2024 Jul 10.

Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer's disease

Yu Guo #  1 , Shi-Dong Chen #  1 , Jia You #  1   2 , Shu-Yi Huang #  1 , Yi-Lin Chen #  1 , Yi Zhang  1 , Lin-Bo Wang  2 , Xiao-Yu He  1 , Yue-Ting Deng  1 , Ya-Ru Zhang  1 , Yu-Yuan Huang  1 , Qiang Dong  1 , Jian-Feng Feng  2   3 , Wei Cheng  1   2   3 , Jin-Tai Yu  4
Affiliations

Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer's disease

Yu Guo et al. Nat Hum Behav. 2024 Oct.

Abstract

Recent expansion of proteomic coverage opens unparalleled avenues to unveil new biomarkers of Alzheimer's disease (AD). Among 6,361 cerebrospinal fluid (CSF) proteins analysed from the ADNI database, YWHAG performed best in diagnosing both biologically (AUC = 0.969) and clinically (AUC = 0.857) defined AD. Four- (YWHAG, SMOC1, PIGR and TMOD2) and five- (ACHE, YWHAG, PCSK1, MMP10 and IRF1) protein panels greatly improved the accuracy to 0.987 and 0.975, respectively. Their superior performance was validated in an independent external cohort and in discriminating autopsy-confirmed AD versus non-AD, rivalling even canonical CSF ATN biomarkers. Moreover, they effectively predicted the clinical progression to AD dementia and were strongly associated with AD core biomarkers and cognitive decline. Synaptic, neurogenic and infectious pathways were enriched in distinct AD stages. Mendelian randomization did not support the significant genetic link between CSF proteins and AD. Our findings revealed promising high-performance biomarkers for AD diagnosis and prediction, with implications for clinical trials targeting different pathomechanisms.

PubMed Disclaimer

References

    1. Johnson, E. C. B. et al. Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat. Neurosci. 25, 213–225 (2022). - PubMed - PMC
    1. van der Kant, R., Goldstein, L. S. B. & Ossenkoppele, R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 21, 21–35 (2020). - PubMed
    1. Sung, Y. J. et al. Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease. Sci. Transl. Med. 15, eabq5923 (2023). - PubMed - PMC
    1. Johnson, E. C. B. et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease. Nat. Med. 29, 1979–1988 (2023). - PubMed - PMC
    1. Del Campo, M. et al. CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat. Aging 2, 1040–1053 (2022). - PubMed - PMC

LinkOut - more resources